GLAUKOS Corp GKOS
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. 10-K, Item 1
- Employees
- 1,094
- Headquarters
- Aliso Viejo, CA
- CEO
- Thomas William Burns
- Next results
- around Jan 12, 2027
GKOS among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
11 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 23, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 10 checks found nothing to note
-
Receivables growing faster than revenueReceivables +78.8% ($60.7M to $108.6M) vs revenue +32.3% ($383.5M to $507.4M), +46.5 pts apart
-
Cash from operations −$14.8M vs net income −$187.7M (FY ending Dec 31, 2025)
9 more checks with nothing to note
-
Inventory +10.2% ($57.7M to $63.6M) vs revenue +32.3% ($383.5M to $507.4M), -22.1 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
The same matters as last year: Classification, completeness, and measurement of customer discounts and revenue related incentive programs
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
11 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
Additionally, U.S. government shutdowns, including the shutdown that occurred in the fourth quarter of 2025, have impacted and could in the future impact certain regulatory agencies relevant to us, such as the U.S. FDA. Significant changes to operations at or the funding of such regulatory agencies could cause decreases in staff or…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
We have and may continue to enter into acquisitions, collaborations, in-licensing agreements, joint ventures and partnerships in order to retain our competitive position within the marketplace, develop new products or expand into new markets. Examples include our acquisitions of Mobius Therapeutics, LLC, DOSE Medical, and Avedro, as…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
Our enterprise resource planning (ERP) system is integral to our ability to accurately and efficiently maintain our books and records, record transactions, and prepare our financial statements. Any disruptions or
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
We have incorporated and continue to further incorporate artificial intelligence into our internal operations. Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business. We have and are continuing to incorporate…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $282.9M | $314.7M | $383.5M | $507.4M |
| Net income | −$99.2M | −$134.7M | −$146.4M | −$187.7M |
| Operating cash flow | −$33.1M | −$57.8M | −$61.3M | −$14.8M |
| Free cash flow | −$63.3M | −$78.0M | −$67.6M | −$22.5M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$507.4M ▲ 32.3% in FY2025−$187.7M in FY2025−$22.5M in FY2025
Recent filings
9 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 12, 2026Gilliam Joseph E (Officer) gave notice of a planned sale of 44,917 shares worth about $11.1M Form 144, approximate sale date Nov 12, 2026, under a 10b5-1 plan adopted Aug 13, 2026
-
8-KNov 6, 2026Regulation FD disclosure 8-K item 7.01
-
Planned saleNov 4, 2026Kliman Gilbert H (Director) gave notice of a planned sale of 2,500 shares worth about $632K Form 144, approximate sale date Nov 4, 2026
-
Planned saleOct 30, 2026Navratil Tomas (Officer) gave notice of a planned sale of 44,436 shares worth about $10.6M Form 144, approximate sale date Oct 30, 2026
-
Planned saleOct 28, 2026Joe Gilliam (President and Chief Operating Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 59,890 shares, runs to Apr 30, 2027
About the company
GLAUKOS Corp, Aliso Viejo, CA · from the 10-K filed Feb 23, 2026
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012. In 2024, we commenced commercialization activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time.
- Headquarters
- Aliso Viejo, CA
- Country
- United States
- Reports in
- USD
- Listed on
- NYSE
- Fiscal year ends
- December 31
- Last results
- Oct 28, 2026
- Incorporated in
- DE
Employees, at the top of the page: "As of December 31, 2025, we had 1,094 full-time employees" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GKOS/export.csv") into a cell.